BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.45 per share versus the Zacks Consensus Estimate of a loss of $2.3. This compares to a loss of $3.36 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.52%. A quarter ago, it was expected that this company would post a loss of $2.72 per share when it actually produced a loss of $1.5, delivering a surprise of +44.85%. Over the last four quarters, the compan ...